ISSN: 2157-2518
Journal of Carcinogenesis & Mutagenesis

OPEN ACCESS Freely available online

Opinion Article

Organ-on-a-Chip Technology: Evaluating Drug Toxicity in Cancer Treatment

Veronica Barbour*

Department of Cancer Medicine, Tulane University, New Orleans, United States of America

DESCRIPTION

The Investigation to develop an effective cancer treatment therapies is an ongoing challenge that necessitates innovative and precise preclinical models. Traditional methods, such as two-dimensional (2D) cell cultures and animal models, often in accurately copy the human tumor microenvironment and predicting clinical outcomes. This technology, which integrates living cells into microfluidic devices, provides a more physiologically relevant environment, enabling more accurate testing of drug efficacy and toxicity.

Organ-on-a-Chip (OOC) Technology

Organ-On-a-Chip technology involves creating microengineered biomimetic systems that replicate the key functions of human organs. These microfluidic devices contain living cells arranged in a manner that mimics tissue and organ-level architecture and functionality. The chips are designed to simulate the physical and chemical environment of human tissues, including aspects such as mechanical forces, fluid flow, and biochemical gradients.

Key features of OOC technology

Control of minute volumes of fluids through channels to simulate blood flow and nutrient delivery. Multiple cell types can be cultured together to mimic the complex interactions within tissues. Ability to apply mechanical forces and monitor cellular responses in real-time.

Advances in cancer-on-a-chip models

Advances in cancer-on-a-chip models are revolutionizing our understanding and treatment of cancer. These innovative platforms replicate the complex microenvironment of tumors, allowing researchers to study cancer progression, drug responses, and metastasis with unprecedented accuracy.

Tumor microenvironment replication: One of the significant advancements in cancer-on-a-chip technology is the ability to recreate the tumor microenvironment accurately. This includes the Extracellular Matrix (ECM), stromal cells, immune cells, and blood vessels. By incorporating these elements, cancer-on-a-chip models can provide a more realistic context for studying tumor behaviour and drug responses.

Personalized medicine: Cancer-on-a-chip technology facilitates for personalized medicine. Patient-derived cells can be used to create individualized cancer models. These personalized chips allow researchers to test the efficacy of different drugs on a specific patient's tumor cells, leading to altered treatment strategies that are more likely to succeed.

Real-time monitoring: Advanced cancer-on-a-chip devices are equipped with sensors that enable real-time monitoring of cellular responses to drugs. Parameters such as cell viability, migration, invasion, and drug uptake can be measured dynamically. This real-time data is invaluable for understanding the immediate and long-term effects of therapeutic agents.

Multi-organ interactions: Multi-organ-on-a-chip systems are being developed to study the interactions between different organs. For cancer research, this is particularly important for understanding metastasis, where cancer cells spread from the primary tumor to distant sites. Multi-organ chips can simulate the journey of cancer cells through the bloodstream and their colonization in secondary organs.

Applications in drug screening

Cancer-on-a-chip models are proving invaluable in drug screening, providing a more efficient and cost-effective approach compared to traditional methods.

Drug efficacy testing: Cancer-on-a-chip models allow for high-throughput screening of potential anticancer drugs. The ability to recreate the tumor microenvironment ensures that drug responses observed in the chips are more predictive of clinical outcomes. Researchers can test a wide range of compounds to identify the most potential candidates for further development.

Studying drug resistance: One of the significant challenges in cancer treatment is drug resistance. Cancer-on-a-chip models can

Correspondence to: Veronica Barbour, Department of Cancer Medicine, Tulane University, New Orleans, United States of America, E-mail: Bveronica@utc.edu

Received: 03-Jun-2024, Manuscript No. JCM-24-25960; **Editor assigned:** 05-Jun-2024, JCM-24-25960 (PQ); **Reviewed:** 19-Jun-2024, QC No. JCM-24-25960; **Revised:** 26-Jun-2024, Manuscript No. JCM-24-25960 (R); **Published:** 03-Jul-2024, DOI:10.35248/2157-2518.24.S44.003

Citation: Barbour V (2024) Organ-on-a-Chip Technology: Evaluating Drug Toxicity in Cancer Treatment. J Carcinog Mutagen. S44.003.

be used to study the mechanisms underlying resistance. By incorporating genetic and phenotypic diversity, these models help identify how tumors adapt to evade therapy and enable the development of strategies to overcome resistance.

Evaluating drug toxicity: OOC technology provides a platform for assessing the toxicity of new drugs. By including healthy tissue alongside tumor cells, researchers can evaluate the selective toxicity of anticancer agents. This helps in identifying drugs that are effective against cancer cells while sparing normal tissues, reducing the risk of adverse side effects.

Immune-oncology studies: The integration of immune cells into cancer-on-a-chip models facilitates for studying immunotherapies. These models can simulate the immune response to tumors and evaluate the efficacy of immune checkpoint inhibitors, CAR-T cell therapies, and other immunotherapeutic approaches

Challenges and future directions

Despite the significant advancements, there are challenges to be addressed in the development and application of cancer-on-a-chip technology.

Standardization: There is a need for standardization in the design and operation of OOC devices to ensure reproducibility and comparability of results across different laboratories.

Scalability: Scaling up the production of these devices for high-throughput screening remains a challenge. Advances in manufacturing techniques are needed to make OOC technology more accessible for widespread use.

Integration with clinical data: The connection between preclinical OOC data and clinical outcomes is potential. This involves integrating OOC findings with clinical data to validate the predictive power of these models.

Organ-on-a-chip technology represents a significant advancement in cancer drug discovery and development. By providing more physiologically relevant models, this technology enhances our ability to predict drug efficacy and toxicity, study tumor biology, and develop personalized treatment strategies. As research progresses, overcoming the current challenges will further solidify the role of cancer-on-a-chip models as indispensable tools in the fight against cancer. The future of cancer therapy is likely to be framed by these innovative technologies, leading to more effective and safer treatments for patients worldwide.